aim to review special safety topics associated with sildenafil and to document the tolerability of 50 and 100mg doses overall and by age in men with erectile dysfunction edmethods data were collated from 67 doubleblind placebocontrolled dbpc trials  14000 men conducted by the manufacturer and from the manufacturers postmarketing safety database 39277 patientsthe dbpc data were stratified by dose starting dose and age  65 and  75 yearsspecial safety topics included cardiovascular risk priapism nonarteritic anterior ischaemic optic neuropathy naion impaired renal and hepatic function drug interactions ienitrates cytochrome p3a4 inhibitors other ed therapies and Î±blockers and incorrect useresults sildenafil was well tolerated at a dose of 50 or 100 mg in men with ed overall in those aged  65 years and in those aged  75 yearsanalyses of the databases did not reveal any causal link between sildenafil and cardiovascular events or any new safety risks relating to cardiovascular events priapism naion hearing loss or drug interactionsin the small number of men with moderate impairment of renal function or hepatic function who were treated with sildenafil in dbpc trials the safety profile was similar to that in men with no impairment of renal or hepatic functionoverdose with sildenafil was rare in the ed populationno new safety issues emerging trends or adverse reactions were identified in conjunction with overdose dependence abuse or misuseconclusion this collated review confirms generally the good tolerability and established safety profile of sildenafil 50 and 100 mg in men with ed and reveals no new safety issues